Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
The IRIS Registry (Intelligent Research in Sight) powered several big data studies this year, most of which will be presented and discussed at AAO 2022 Gather, the 126th annual meeting of the American Academy of Ophthalmology.
In a study of more than 80 men and women from Baltimore, Maryland, Johns Hopkins researchers have added to evidence that COVID-19 booster shots are essential for maintaining long-term immunity against infection, particularly among older adults.
Researchers opined on the use of live-attenuated whole virus vaccines as COVID-19 vaccines.
"Welcome to ViruStop!" Recently, ACROBiosystems officially announced the launch of a new brand, ViruStop. ViruStop is specifically designed for virus research and development, committing to accelerating the process of infectious diseases vaccine research, development and approval.
With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.
Today, CDC continues to lean forward with an aggressive public health response to the monkeypox outbreak by activating its Emergency Operations Center (EOC).
Researchers assessed the prevalence of antibodies that neutralize the type I interferon antiviral activity and reactivate herpesviruses such as herpes simplex virus types 1 and 2 and/or cytomegalovirus infections in patients with critical COVID-19.
Anthrax has a scary reputation. Widely known to cause serious lung infections in humans and unsightly, albeit painless, skin lesions in livestock and people, the anthrax bacterium has even been used as a weapon of terror.
A deep look into a nationwide mass vaccination setting in Israel revealed that the BNT162b2 (Pfizer–BioNTech) vaccine is not linked with an elevated risk of a majority of the adverse events under study, with the exception of myocarditis. However, even that potentially severe adverse event is much more pervasive following the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), found a new study published in the New England Journal of Medicine (NEJM).
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the safety of the Pfizer/BioNTech BNT162B2 vaccine against COVID-19.
A new review published in the journal Canadian Family Physician describes skin diseases caused by the coronavirus disease 2019 (COVID-19).
Vivid photos of the red "COVID arm" rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy.
Effectively and safely protecting against disease--this is what makes vaccines a vital and successful public health tool that saves lives and safeguards health and well-being. Today, vaccines shield us from more than 20 life-threatening diseases.
Posts are showing up all over social media tying Covid-19 vaccinations to shingles and other painful skin disorders.
Immunizing children against chickenpox would save money, but offering shingles vaccinations to all 65-year-olds would not. These are examples of findings in a University of Gothenburg thesis exploring the cost-effectiveness of Sweden's national vaccination programs.
With multiple COVID-19 vaccines rapidly heading toward approval, optometrists and dentists are pushing for the authority to immunize patients during routine eye exams and dental cleanings.
A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston.
Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.
A new study published in the preprint server bioRxiv in September 2020 reports on the structure of this protein, as revealed by cryo-electron microscopy (cryoEM).
The new Childhood and Adolescent Immunization Schedule and the Adult Immunization Schedule for 2020 are out, just released by the Advisory Committee on Immunization Practices (ACIP). This is an annual event following its yearly revision.